Citations

Institution: Mayo Clinic Clear

Showing 10 of 108135 citations.

Allergic Inflammatory Response to Short Ragweed Allergenic Extract in HLA-DQ Transgenic Mice Lacking CD4 Gene
Chapoval, Svetlana P. , Iijima, Koji, Marietta, Eric, Smart, Michele, Chapoval, Andrei I. , Andrews, Amy G., David, Chella S.

The Journal of Immunology | April 20, 2014 | Volume: 168 | Issue: 2 | Pages: 890-899

10.4049/jimmunol.168.2.890 | PMID 11777987 Get It

Abstract To investigate the role of HLA-DQ molecules and/or CD4+ T cells in the pathogenesis of allergic asthma, we generated HLA-DQ6 and HLA-DQ8 transgenic mice lacking endogenous class II (Aβnull) and CD4 genes and challenged them intranasally with short ragweed allergenic extract (SRW). We found that DQ6/CD4null mice developed a strong eosinophilic infiltration into the bronchoalveolar lavage and lung tissue, while DQ8/CD4null mice were normal. However, neither cytokines nor eosinophil peroxidase in the bronchoalveolar lavage of DQ6/CD4null mice was found. In addition, the airway reactivity to methacholine was elevated moderately in DQ6/CD4null mice compared with the high response in DQ/CD4+ counterparts and was only partially augmented by CD4+ T cell transfer. The DQ6/CD4null mice showed Th1/Th2-type cytokines and SRW-specific Abs in the immune sera in contrast to a direct Th2 response observed in DQ6/CD4+ mice. The proliferative response of spleen mononuclear cells and peribronchial lymph node cells demonstrated that the response to SRW in DQ6/CD4null mice was mediated by HLA-DQ-restricted CD4−CD8−NK1.1− T cells. FACS analysis of PBMC and spleen mononuclear cells demonstrated an expansion of double-negative (DN) CD4−CD8−TCRαβ+ T cells in SRW-treated DQ6/CD4null mice. These cells produced IL-4, IL-5, IL-13, and IFN-γ when stimulated with immobilized anti-CD3. IL-5 ELISPOT assay revealed that DN T cells were the cellular origin of IL-5 in allergen-challenged DQ6/CD4null mice. Our study shows a role for HLA-DQ-restricted CD4+ and DN T cells in the allergic response.
Collagen gel contraction as a measure of fibroblast function in carpal tunnel syndrome
Yang, Tai‐Hua , Thoreson, Andrew R. , Gingery, Anne , An, Kai‐Nan , Zhao, Chunfeng , Amadio, Peter C. , Larson, Dirk R. , Gingery, Anne

Journal of Biomedical Materials Research Part A | April 20, 2014 | Volume: 103 | Issue: 2 | Pages: 574-580

10.1002/jbm.a.35200 | PMID 24753289 Get It

AbstractNoninflammatory subsynovial connective tissue (SSCT) fibrosis with nerve compression is a prominent feature of carpal tunnel syndrome (CTS). Studies have shown that SSCT matrix synthesis and material property changes in CTS are associated with increased activity of transforming growth factor (TGF)‐β1. The aim of this study were to (1) investigate the ability of SSCT fibroblasts from CTS patients and unaffected individuals to contract a collagen gel ring and (2) determine how the addition of TGF‐β1 affects this ability. SSCT fibroblasts from three normal cadavers and three age‐matched female patients who had undergone surgery for CTS were used. Results showed patient cell‐seeded gels had a significantly higher contraction rate (p < 0.001) than control cells, and fully contracted gel rings possessed a significantly higher tensile strength (p = 0.003) and stiffness (p < 0.001). Furthermore, TGF‐β1 significantly intensified contraction rate (p < 0.001), tensile strength (p < 0.001), and stiffness (p < 0.001). In conclusion, SSCT cells from normal donors and CTS patients contract collagen gel rings differently, and this ability is affected by TGF‐β1 treatment. This cell‐seeded collagen gel model may be useful for developing new methods of stopping or eliminating the effect of TGF‐β1 on the SSCT fibroblasts and surrounding matrix, which might aid in the identification of medical treatment for CTS. © 2014 Wiley Periodicals, Inc. J Biomed Mater Res Part A: 103A: 574–580, 2015.
Diabetes, incretin hormones and cardioprotection
Myat, Aung , Redwood, Simon , Yellon, Derek M. , Marber, Michael , Gersh, Bernard J. , Marber, Michael

Heart | April 19, 2014 | Volume: 100 | Issue: 19 | Pages: 1550-1561

10.1136/heartjnl-2012-303242 | PMID 24747994 Get It

Ex‐vivo testing and preclinical heterotopic thoracic cardiac xenotransplantation of multi‐transgenic organs
Mayr, Tanja, Guethoff, Sonja , Buchholz, Stefan, Werner, Fabian, Baehr, Andrea , Klymiuk, Nikolai , Wuensch, A., Wolf, Eckhart, Belka, Claus , Ayares, David , Niemann, Heiner , Bongoni, Anjan K. , McGregor, Christopher G.A. , Reichart, Bruno , Brenner, Paolo , Abicht, Jan‐Michael , Petersen, Björn , Rieben, Robert

Xenotransplantation | April 19, 2014 | Volume: 21 | Issue: 2 | Pages: 190-191

10.1111/xen.12083_14 Get It

The heterotopic thoracic pig‐to‐baboon heart transplantation has been established by our group as a safe preclinical model. Since the recipient's own heart remains in place, it is possible to evaluate immunological reactions of various types and the symptoms of the thrombotic microangiopathy under working heart conditions. However, these experiments are complex and costly. In order to limit the number of transplants, we tested our multi‐transgenic porcine donor hearts in an ex‐vivo perfusion model first.Ex‐vivo model: Both beating ventricles were perfused with heparinized freshly drawn human whole blood using a centrifugal pump and a membrane oxygenator. During 3 h of observation, cardiac function parameters were obtained continuously; specimens from the perfusate, coronary sinus blood, and myocardial biopsies were assessed. Various genetically modified porcine donor hearts were tested; we are currently evaluating the impact of human thrombomodulin on the porcine microcirculation; the efficacy of complement regulation is another work package.Pig‐to‐baboon heterotopic cardiac xenotransplantation: In our latest group, seven baboons received five double (Gal‐KO/hCD46), and two triple (Gal‐KO/hCD46/hTM resp./HLA‐E) transgenic pig hearts. Our immunosuppressive regimen included preoperative anti‐CD20‐antibody, bortezomib, dexamethasone and cyclophosphamide; postoperatively, ATG, tacrolimus, MMF, anti‐CD20‐antibody, bortezomib and dexamethasone were administered. Total lymph node irradiation (6 Gy) was applied on postoperative day five.The triple transgenic hearts survived 35 and 37 days respectively. Both hearts maintained function throughout the experiment. Both recipients succumbed to fungal infections. Humoral rejection was seen only once. The next barrier appears to be the complex event of thrombotic microangiopathy that needs to be addressed with the additional expression of human thrombomodulin strategies.
Adult polyglucosan body disease with GBE1 haploinsufficiency and concomitant frontotemporal lobar degeneration
Bit‐Ivan, Esther N., Lee, K.‐J. , Gitelman, Darren R. , Weıntraub, Sandra , Rademakers, Rosa , Isaacs, Adrian M. , Hatanpaa, Kimmo J. , White, Charles L. , Mao, Qinwen , Akman, Orhan, DiMauro, Salvatore, Bigio, Eileen H. , Mesulam, Marsel M. , White, Charles L , Mao, Qinwen

Neuropathology and Applied Neurobiology | April 19, 2014 | Volume: 40 | Issue: 6 | Pages: 778-782

10.1111/nan.12144 | PMID 24750115 Get It

Shorter (≤6 months) versus longer (≥12 months) duration dual antiplatelet therapy after drug eluting stents: A meta‐analysis of randomized clinical trials
Pandit, Anil , Hakim, Fayaz A., Fortuin, F. David , Giri, Smith

Catheterization and Cardiovascular Interventions | April 19, 2014 | Volume: 85 | Issue: 1 | Pages: 34-40

10.1002/ccd.25520 | PMID 24753084 Get It

ObjectiveOptimal duration of dual antiplatelet therapy (DAPT), defined as use of both aspirin and a P2Y12 receptor inhibitor, after implantation of drug eluting stents (DES) is still subject of ongoing debate. We systematically review efficacy and safety of ≤6 months versus ≥12 months DAPT after implantation of DES.MethodsPubMed, Scopus, Cochrane, and clinicaltrials.gov databases were searched for studies published until 30th November 2013. The studies were limited to randomized clinical trials. Independent observers abstracted the data on outcomes, characteristics, and qualities of studies included. Random effect model was employed for meta‐analysis. Heterogeneity of studies included was analyzed using I2 statistics.ResultsIn four randomized clinical trials published involving 8,163 patients with DES, 4,081 patients were randomized to shorter and 4,082 patients to longer duration DAPT. The P2Y12 receptor inhibitor used in all four studies was clopidogrel. Longer duration of DAPT did not reduce risk of all cause mortality (pooled OR 0.89, 95% CI 0.67–1.17, P = 0.4, I2 = 0%), myocardial infarction (pooled OR 1.16, 95% CI 0.85–1.57, P = 0.35, I2 = 0%) cardiac death (pooled OR 0.88, 95% CI 0.61–1.25, P = 0.47, I2 = 0%), stent thrombosis (pooled OR 1.29, 95% CI 0.76–2.21, P = 0.35, I2 = 0%) or cerebrovascular accidents (pooled OR 0.73, 95% CI 0.41–1.27, P = 0.26, I2 = 0%). Longer duration of DAPT was associated with increased risk of TIMI major bleeding (pooled OR 0.51, 95% CI 0.29–0.89, P = 0.02, I2 = 0%).ConclusionThere was no difference in efficacy outcomes between ≤6 months of DAPT and ≥12 months of DAPT in patients with coronary artery disease and DES implantation. Moreover, longer duration of DAPT is associated with increased risk of bleeding complications. © 2014 Wiley Periodicals, Inc.
Type 1 versus Type 2 calreticulin mutations in essential thrombocythemia: A collaborative study of 1027 patients
Tefferi, Ayalew , Wassie, Emnet A, Guglielmelli, Paola , Gangat, Naseema , Belachew, Alem A. , Finke, Christy M. , Ketterling, Rhett P. , Hanson, Curtis A. , Pardanani, Animesh , Wolanskyj, Alexandra P. , Maffioli, Margherita , Casalone, Rosario , Pacilli, Annalisa , Passamonti, Francesco , Lasho, Terra L. , Vannucchi, Alessandro M. , Wolanskyj-Spinner, Alexandra P , Ketterling, Rhett P , Passamonti, Francesco , Guglielmelli, Paola

American Journal of Hematology | April 19, 2014 | Volume: 89 | Issue: 8 | Pages: No page available

10.1002/ajh.23743 | PMID 24753125 Get It

CALR (calreticulin) trails JAK 2 as the second most mutated gene in essential thrombocythemia (ET). Mutant CALR in ET is a result of frameshift mutations, caused by exon 9 deletions or insertions; type‐1, 52‐bp deletion (p.L367fs*46), and type‐2, 5‐bp TTGTC insertion (p.K385fs*47) variants constitute more than 80% of these mutations. The current study includes a total of 1027 patients divided into test ( n = 402) and validation ( n = 625) cohorts. Among the 402 ET patients in the test cohort, 227 (57%) harbored JAK 2, 11 (3%) Myeloproliferative leukemia virus oncogene ( MPL ), and 114 (28%) CALR mutations; 12% were wild‐type for all three mutations (i.e., triple‐negative). Among the 114 patients with CALR mutations, 51 (45%) displayed type‐1 and 44 (39%) type‐2 variants; compared to mutant JAK 2, both variants were associated with higher platelet and lower hemoglobin and leukocyte counts. However, male sex was associated with only type‐1 ( P = 0.005) and younger age with type‐2 ( P = 0.001) variants. Notably, platelet count was significantly higher in type‐2 vs. type‐1 CALR ‐mutated patients ( P = 0.03) and the particular observation was validated in the validation cohort that included 111 CALR ‐mutated ET patients ( P = 0.002). These findings, coupled with the recent demonstration of preferential expression of mutant and wild‐type CALR in megakaryocytes, suggest differential effects of CALR variants on thrombopoiesis. Am. J. Hematol. 89:E121–E124, 2014. © 2014 Wiley Periodicals, Inc.
β-Amyloidosis and neurodegeneration in Alzheimer disease
Knopman, David S.

Neurology | April 19, 2014 | Volume: 82 | Issue: 20 | Pages: 1756-1757

10.1212/wnl.0000000000000438 | PMID 24748669 Get It

Human Bone Marrow: A Reservoir for “Enhanced Effector Memory” CD8+ T Cells with Potent Recall Function
Zhang, Xiaoyu , Lin, Wei, Voss, Stephen G. , Hinkley, Lucinda, Westergren, Melissa, Tian, Guo‐Liang , Berry, Daniel J. , Lewellen, D. C., Vile, Richard G. , Strome, Scott E. , Dong, Haidong , Chen, Lieping , Färber, Donna L. , Berry, Daniel J

The Journal of Immunology | April 18, 2014 | Volume: 177 | Issue: 10 | Pages: 6730-6737

10.4049/jimmunol.177.10.6730 | PMID 17082586 Get It

Abstract The role of human bone marrow (BM) CD8+ T cells in the immune response to viral Ags is poorly defined. We report here the identification and characterization of a functionally enhanced effector memory CD8+ T cell population (TEM) in the BM of patients undergoing total joint replacement for osteoarthritis. These BM-derived TEM differ strikingly from correlate cells in peripheral blood (PB), expressing elevated levels of CD27, HLA-DR, CD38, CD69, and unique patterns of chemokine receptors. Interestingly, while BM TEM have low levels of resting perforin and granzyme B, these molecules evidence profound up-regulation in response to TCR stimulation resulting in enhanced cytotoxic potential. Moreover, compared with the TEM subset in PB, BM CD8+ TEM cells demonstrate a more vigorous recall response to pooled viral Ags. Our results reveal that human BM serves as a repository for viral Ag-specific TEM with great therapeutic potential in vaccine development.
Cyclooxygenase-2 Inhibitor Enhances the Efficacy of a Breast Cancer Vaccine: Role of IDO
Basu, Gargi D. , Tinder, Teresa L., Tu, Tony, Hattrup, Christine L., Pockaj, Barbara A. , Mukherjee, Pinku , Bradley, Judy Martina

The Journal of Immunology | April 18, 2014 | Volume: 177 | Issue: 4 | Pages: 2391-2402

10.4049/jimmunol.177.4.2391 | PMID 16888001 Get It

Abstract We report that administration of celecoxib, a specific cyclooxygenase-2 (COX-2) inhibitor, in combination with a dendritic cell-based cancer vaccine significantly augments vaccine efficacy in reducing primary tumor burden, preventing metastasis, and increasing survival. This combination treatment was tested in MMTV-PyV MT mice that develop spontaneous mammary gland tumors with metastasis to the lungs and bone marrow. Improved vaccine potency was associated with an increase in tumor-specific CTLs. Enhanced CTL activity was attributed to a significant decrease in levels of tumor-associated IDO, a negative regulator of T cell activity. We present data suggesting that inhibiting COX-2 activity in vivo regulates IDO expression within the tumor microenvironment; this is further corroborated in the MDA-MB-231 human breast cancer cell line. Thus, a novel mechanism of COX-2-induced immunosuppression via regulation of IDO has emerged that may have implications in designing future cancer vaccines.